Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $23.53, for a total value of $470,600.00. Following the completion of the sale, the insider directly owned 43,298 shares of the company’s stock, valued at $1,018,801.94. The trade was a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Kevin Patrick Danahy also recently made the following trade(s):

• On Tuesday, February 17th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $23.63, for a total transaction of $472,600.00.
• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $21.45, for a total transaction of $429,000.00.
• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Price Performance

Shares of NASDAQ:PLSE traded up $0.66 on Tuesday, reaching $23.67. The company’s stock had a trading volume of 303,171 shares, compared to its average volume of 434,878. Pulse Biosciences, Inc has a 52-week low of $12.56 and a 52-week high of $26.30. The stock’s 50-day moving average is $15.75 and its two-hundred day moving average is $15.90. The stock has a market capitalization of $1.60 billion, a P/E ratio of -20.95 and a beta of 1.77.

Wall Street Analyst Weigh In

A number of equities analysts have commented on PLSE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $26.00.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its holdings in Pulse Biosciences by 2.7% during the third quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock worth $14,248,000 after purchasing an additional 21,424 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Pulse Biosciences by 7.2% in the second quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock valued at $7,538,000 after buying an additional 33,744 shares in the last quarter. State Street Corp increased its position in shares of Pulse Biosciences by 6.0% in the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after buying an additional 25,187 shares in the last quarter. Brooklyn Investment Group raised its stake in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after buying an additional 100,081 shares during the last quarter. Finally, Portolan Capital Management LLC purchased a new stake in shares of Pulse Biosciences in the 3rd quarter worth about $1,809,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.